June 2025 in “Journal of the Pakistan Medical Association” 2dDR may help regrow hair in male pattern baldness.
37 citations
,
February 2010 in “Psychoneuroendocrinology” Androgen self-administration might be controlled by membrane receptors, not nuclear ones.
January 2005 in “世界胃肠病学杂志:英文版(电子版)” Etoposide makes radiation therapy more effective against tumors without major side effects.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
84 citations
,
February 1981 in “Journal of Endocrinology” Epidermal growth factor slows hair and body growth in mice.
60 citations
,
May 2015 in “Archives of dermatological research” PPAR agonists show promise for skin conditions but need more research before being a main treatment.
September 2025 in “Blood Advances” Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.
4 citations
,
April 2024 in “Cellular and Molecular Biology” Injectable platelet-rich fibrin is better than platelet-rich plasma for promoting hair growth.
10 citations
,
August 2024 in “Neuroscience & Biobehavioral Reviews” Neurosteroids may help treat disorders with too much dopamine activity.
January 2007 in “El Servicio de Difusión de la Creación Intelectual (National University of La Plata)” Combining D-004 and finasteride is more effective at reducing prostate enlargement than using either alone.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
34 citations
,
February 1992 in “Naunyn-schmiedebergs Archives of Pharmacology” Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
2 citations
,
September 2025 in “Frontiers in Pharmacology” Empagliflozin helps heal diabetic wounds in rats by reducing inflammation and oxidative stress.
9 citations
,
October 2015 in “Journal of Cutaneous Pathology” Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
8 citations
,
August 2011 in “Journal of Medicinal Food” D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.
Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
13 citations
,
January 2015 in “Steroids” The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
3 citations
,
October 2011 in “JAT. Journal of applied toxicology/Journal of applied toxicology” Doxazosin mesylate and saw palmetto cause genetic changes in fruit flies.
July 2022 in “British Journal of Dermatology”
February 2025 in “Intisari Sains Medis” PDRN from salmon may slow skin aging by improving skin quality and reducing inflammation.
July 2003 in “Pediatrics in review” In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
January 2013 in “Scholarworks (University of Massachusetts Amherst)” FERONIA regulates plant growth, pollen interactions, and sugar signaling.
29 citations
,
February 2007 in “Hormone and metabolic research” Blocking the androgen receptor in skin cells reduces their growth response to male hormones, suggesting a possible treatment for skin conditions linked to androgens.
24 citations
,
July 2017 in “Structure” FGF9 controls which receptors it binds to through a process where two FGF9 molecules join, and changes in FGF9 can lead to incorrect receptor activation.
May 2018 in “KU ScholarWorks (The University of Kansas)” Targeting 5α-reductase type 1 may help manage Tourette-like symptoms.
April 2023 in “Journal of Investigative Dermatology” cp-asiAR may effectively treat hair loss by targeting androgen receptors.